SFCM
EWTX icon

Seven Fleet Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Seven Fleet Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-11,701
Closed -$369K – 102
2026
Q1 		$369K Buy
11,701
+9,701
+485% +$280K 0.12% 91
2025
Q4 		$49.6K Buy
+2,000
New +$40.1K 0.03% 79

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Seven Fleet Capital Management's EWTX Position: Q2 2026 in Review

Seven Fleet Capital Management sold out of Edgewise Therapeutics (EWTX) in Q2 2026, closing a stake of 11,701 shares — an estimated $369K sold.

Seven Fleet Capital Management first reported a position in EWTX in Q4 2025 and held it in 2 quarters. The position peaked at $369K in Q1 2026. 226 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Seven Fleet Capital Management reported no remaining Edgewise Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Seven Fleet Capital Management sold 11,701 Edgewise Therapeutics shares in Q2 2026, an estimated $369K.
  • Seven Fleet Capital Management first reported a position in Edgewise Therapeutics in Q4 2025 and held it in 2 quarters.
  • Seven Fleet Capital Management's Edgewise Therapeutics position peaked at $369K in Q1 2026.
  • 226 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Seven Fleet Capital Management's 13F filing for Q2 2026, filed 17 Aug 2026.